AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30927859 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity of GLUT
Number of subjects: 0
Study 28183466 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel self-expanding TAV bioprosthesis
Number of subjects: 241
Study 26049076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence-combining (SC) intervention
Number of subjects: 52
Study 26049076 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative-based (NAR) intervention
Number of subjects: 52
Study 26049076 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 52
Study 23813620 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg single dose
Number of subjects: 30
Study 23813620 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg single dose
Number of subjects: 30
Study 23813620 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg single dose
Number of subjects: 30
Study 23813620 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg multiple doses
Number of subjects: 30
Study 21645394 — intervention group
Group type: EXPERIMENTAL
Intervention: Early participants
Number of subjects: 1668
Study 21645394 — intervention group
Group type: EXPERIMENTAL
Intervention: Late participants
Number of subjects: 1668
Study 21645394 — intervention group
Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 1668
Study 19192836 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (Kuraray) with double the application time of the primer
Number of subjects: 32
Study 19192836 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE (Ivoclar‐Vivadent) with double the application time of the primer
Number of subjects: 32
Study 19192836 — intervention group
Group type: EXPERIMENTAL
Intervention: Futurabond NR (Voco) with double the application time of the primer
Number of subjects: 32
Study 19192836 — intervention group
Group type: EXPERIMENTAL
Intervention: One Up Bond F Plus (J Morita) with double the application time of the primer
Number of subjects: 32
Study 19192836 — intervention group
Group type: COMPARATOR
Intervention: Control application time of the primer for all adhesive systems
Number of subjects: 32
Study 17081163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg twice daily for 3 days
Number of subjects: 50
Study 17081163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15579757 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (4 or 8 mg/d) for 26 weeks
Number of subjects: 0
Study 15579757 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 0
Study 15579757 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone for 52 weeks
Number of subjects: 0
Study 15579757 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide for 52 weeks
Number of subjects: 0
Study 11716833 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback presented in the left visual field (LVF)
Number of subjects: 0
Study 11716833 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback presented in the right visual field (RVF)
Number of subjects: 0
Study 11716833 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback stimuli were faces (smiling or frowning)
Number of subjects: 0
Study 11716833 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback stimuli were colored squares
Number of subjects: 0
Study 11716833 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback stimuli were verbal feedback
Number of subjects: 0
Study 9422013 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical resection of the endometrium (n = 93)
Number of subjects: 197
Study 9422013 — intervention group
Group type: COMPARATOR
Intervention: Medical treatments (n = 94)
Number of subjects: 197
Study 8101550 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-immune plasma (250 mL every 4 weeks)
Number of subjects: 63
Study 8101550 — intervention group
Group type: COMPARATOR
Intervention: HIV antibody-negative plasma (250 mL every 4 weeks)
Number of subjects: 63
Study 3552925 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone therapy (28-day course)
Number of subjects: 15
Study 3552925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31099272 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment program
Number of subjects: 213
Study 31099272 — intervention group
Group type: COMPARATOR
Intervention: Supported employment program (sub-group)
Number of subjects: 213
Study 30141288 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG guided point injection at Renying (ST 9), administered three times a week for 2 weeks, in addition to conventional drugs and rehabilitation training.
Number of subjects: 60
Study 30141288 — intervention group
Group type: COMPARATOR
Intervention: Conventional drugs combined with rehabilitation training, administered once daily for 2 weeks.
Number of subjects: 60
Study 27573938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily
Number of subjects: 48
Study 27573938 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1,000 mg daily
Number of subjects: 48
Study 27573938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25648350 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism Adaptation (PA)
Number of subjects: 70
Study 25648350 — intervention group
Group type: COMPARATOR
Intervention: Sham Adaptation (SA)
Number of subjects: 70
Study 23512320 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-weighing intervention using smart scales and e-mail
Number of subjects: 91
Study 20924617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine
Number of subjects: 50
Study 20924617 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-ketamine
Number of subjects: 50
Study 18219456 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout prescription I
Number of subjects: 107
Study 18219456 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout prescription II
Number of subjects: 107
Study 18219456 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout prescription III
Number of subjects: 107
Study 18219456 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin and Benzobromarone (control)
Number of subjects: 107
Study 16173861 — intervention group
Group type: EXPERIMENTAL
Intervention: PrimeTime intervention targeting child competencies
Number of subjects: 86
Study 16173861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch Buddy intervention targeting peer ecology
Number of subjects: 86
Study 12823646 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 1.25 mg + Aspirin 75 mg daily (W/A)
Number of subjects: 668
Study 12823646 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation (C)
Number of subjects: 668
Study 11905682 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer using serum prostate specific antigen measurement, followed by transrectal ultrasound scanning and biopsy.
Number of subjects: 0
Study 11905682 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy, radical radiotherapy, and monitoring with treatment if required.
Number of subjects: 0
Study 11905682 — intervention group
Group type: EXPERIMENTAL
Intervention: Future developments in diagnostic testing, molecular markers of progression, and early chemoprevention.
Number of subjects: 0
Study 9001835 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-D-glucosamine (NAG)
Number of subjects: 10
Study 9001835 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric N-acetyl-D-glucosamine (POLY-Nag)
Number of subjects: 10
Study 9001835 — intervention group
Group type: COMPARATOR
Intervention: NAG and POLY-Nag
Number of subjects: 10
Study 1464336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 190
Study 1464336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 1464336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both metoprolol and placebo (inability to perform predischarge stress testing)
Number of subjects: 190
Study 1464336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both metoprolol and placebo (low predischarge exercise capacity)
Number of subjects: 190
Study 1464336 — intervention group
Group type: EXPERIMENTAL
Intervention: ST segment shift > or = 1 mm
Number of subjects: 190
Study 1464336 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of metoprolol
Number of subjects: 190
Study 6143964 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4237 vaccine
Number of subjects: 178
Study 6143964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 31486253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tramadol (0.5 mg/kg)
Number of subjects: 350
Study 31486253 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (0.5 mg/kg and 0.75 mg/kg)
Number of subjects: 350
Study 31486253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5 mcg/kg and 0.75 mcg/kg)
Number of subjects: 350
Study 31486253 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 350
Study 29502373 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative precision nutrition treatment
Number of subjects: 71
Study 29502373 — intervention group
Group type: COMPARATOR
Intervention: Traditional postoperative nutrition treatment
Number of subjects: 71
Study 26902132 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV monitoring
Number of subjects: 90
Study 26902132 — intervention group
Group type: COMPARATOR
Intervention: CVP monitoring
Number of subjects: 90
Study 25251377 — intervention group
Group type: EXPERIMENTAL
Intervention: Zeaxanthin only (20 mg/day; n=29)
Number of subjects: 92
Study 25251377 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed formulation (26 mg/day zeaxanthin, 8 mg/day lutein, and 190 mg/day mixed omega‐3 fatty acids; n=25)
Number of subjects: 92
Study 25251377 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 92
Study 23158830 — intervention group
Group type: EXPERIMENTAL
Intervention: DE-PLAN, a structured educational intervention program focused on changing healthy lifestyles (diet and physical activity)
Number of subjects: 1089
Study 23158830 — intervention group
Group type: COMPARATOR
Intervention: Usual care for the prevention and treatment of DM2 currently provided in Osakidetza
Number of subjects: 1089
Study 21061788 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm; n = 159)
Number of subjects: 288
Study 21061788 — intervention group
Group type: COMPARATOR
Intervention: conventional surgery or exclusive radiotherapy (CONV arm; n = 129)
Number of subjects: 288
Study 21061788 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm)
Number of subjects: 288
Study 21061788 — intervention group
Group type: COMPARATOR
Intervention: conventional surgery or exclusive radiotherapy (CONV arm)
Number of subjects: 288
Study 17922895 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hGH administered by cool.click 2
Number of subjects: 38
Study 17922895 — intervention group
Group type: COMPARATOR
Intervention: r-hGH administered by needle and syringe
Number of subjects: 38
Study 16320942 — intervention group
Group type: EXPERIMENTAL
Intervention: Test sustained-release indapamide formulation (3 mg)
Number of subjects: 20
Study 16320942 — intervention group
Group type: COMPARATOR
Intervention: Reference sustained-release indapamide formulation (3 mg)
Number of subjects: 20
Study 11880565 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (ferrous sulfate 300 mg/tablet)
Number of subjects: 397
Study 11880565 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (ferrous sulfate 300 mg/tablet)
Number of subjects: 397
Study 11880565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 9460148 — intervention group
Group type: EXPERIMENTAL
Intervention: Act-as-usual group (encouraged to continue normal activities)
Number of subjects: 201
Study 9460148 — intervention group
Group type: COMPARATOR
Intervention: Soft neck collar group (given time off from work and immobilized)
Number of subjects: 201
Study 7649495 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (200 mg during induction of anesthesia and 100 mg after starting extracorporeal circulation)
Number of subjects: 22
Study 7649495 — intervention group
Group type: COMPARATOR
Intervention: Control (no allopurinol)
Number of subjects: 22
Study 2669552 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with dog or cat extract (n = 14), subcutaneous injections with alum-adsorbed depot extract (Alutard-SQ), maintenance dose of 100,000 SQ-U or maximum tolerated dose.
Number of subjects: 27
Study 2669552 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy (n = 13).
Number of subjects: 27
Study 2669552 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with dog or cat extract (n = 14).
Number of subjects: 27
Study 4455095 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a two choice simultaneous visual discrimination task with brightness or shape as the relevant dimension.
Number of subjects: 0
Study 31146544 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg monthly
Number of subjects: 383
Study 31146544 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg monthly (initial dosage)
Number of subjects: 383
Study 28582403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalcipherol (300,000 IU) combined with standard treatment (methotrexate and glucocorticoids)
Number of subjects: 39
Study 28582403 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (methotrexate and glucocorticoids) without cholecalcipherol
Number of subjects: 39
Study 28582403 — intervention group
Group type: EXPERIMENTAL
Intervention: eRA patients
Number of subjects: 39
Study 23855643 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic regimen (pre- and post-operative)
Number of subjects: 13
Study 23855643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 23454858 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation of the medial malleolus
Number of subjects: 100
Study 23454858 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment of the medial malleolus
Number of subjects: 100
Study 21626320 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 23
Study 21626320 — intervention group
Group type: COMPARATOR
Intervention: Conventional ligature
Number of subjects: 23
Study 19369574 — intervention group
Group type: EXPERIMENTAL
Intervention: High-purine meal
Number of subjects: 20
Study 19369574 — intervention group
Group type: COMPARATOR
Intervention: Low-purine meal
Number of subjects: 20
Study 16764619 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian drilling (LOD) plus 1700 mg per day of metformin for 6 months
Number of subjects: 42
Study 16764619 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling (LOD) alone
Number of subjects: 42
Study 15233705 — intervention group
Group type: EXPERIMENTAL
Intervention: Asimadoline 0.5 mg
Number of subjects: 20
Study 15233705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12240757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 10
Study 12240757 — intervention group
Group type: EXPERIMENTAL
Intervention: Videobronchoscopy
Number of subjects: 10
Study 12240757 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube sizing
Number of subjects: 10
Study 9524516 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable tension-band fixation (B)
Number of subjects: 38
Study 9524516 — intervention group
Group type: COMPARATOR
Intervention: Metallic tension-band fixation (M)
Number of subjects: 38
Study 7644080 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 100 mg
Number of subjects: 3
Study 7644080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 2758733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion of cimetidine (300 mg every 6 hours)
Number of subjects: 26
Study 2758733 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cimetidine (37.5 mg per hour with a priming dose of 300 mg for 15 minutes)
Number of subjects: 26
Study 792850 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG) in addition to prednisone and azathioprine
Number of subjects: 30
Study 792850 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 30
Study 28776062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice (20-min sessions weekly for one academic semester)
Number of subjects: 0
Study 28776062 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mindfulness practice)
Number of subjects: 0
Study 25871786 — intervention group
Group type: EXPERIMENTAL
Intervention: CASUS® group (using online cases for preparation)
Number of subjects: 0
Study 25871786 — intervention group
Group type: COMPARATOR
Intervention: Book group (using a textbook)
Number of subjects: 0
Study 22066521 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping HAND intervention group
Number of subjects: 40
Study 22066521 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular paediatric care)
Number of subjects: 40
Study 21967363 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 1500
Study 21967363 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 1500
Study 21967363 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 1500
Study 21967363 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1500
Study 19386814 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic pre-conditioning (RIPC)
Number of subjects: 42
Study 19386814 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 17786601 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser pointer used in group B to improve targeting capabilities of the cameras.
Number of subjects: 40
Study 17786601 — intervention group
Group type: COMPARATOR
Intervention: Standard navigated TKR without laser pointer in group A.
Number of subjects: 40
Study 15284269 — intervention group
Group type: EXPERIMENTAL
Intervention: M-R catheters (minocycline and rifampin)
Number of subjects: 356
Study 15284269 — intervention group
Group type: COMPARATOR
Intervention: Nonimpregnated catheters
Number of subjects: 356
Study 11157316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 56
Study 11157316 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 56
Study 9022872 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine use
Number of subjects: 162
Study 9022872 — intervention group
Group type: COMPARATOR
Intervention: Caffeine abstinence
Number of subjects: 162
Study 7884021 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 113
Study 30502311 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 40
Study 30502311 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (no noninvasive ventilation)
Number of subjects: 40
Study 28859383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alginate (10 mL of Gaviscon Advance)
Number of subjects: 50
Study 28859383 — intervention group
Group type: COMPARATOR
Intervention: Water (10 mL)
Number of subjects: 50
Study 25847503 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical autologous platelet-rich gel (APG) plus standard treatment
Number of subjects: 117
Study 25847503 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 117
Study 25847503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study 25847503 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical APG application
Number of subjects: 117
Study 25847503 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term survival and recurrence rates
Number of subjects: 117
Study 24080677 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 32
Study 24080677 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Group Therapy
Number of subjects: 32
Study 21422207 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 300 mg
Number of subjects: 8
Study 21422207 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole 200 mg
Number of subjects: 8
Study 18795972 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated hypertensive patients
Number of subjects: 1419
Study 16874214 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 30
Study 16874214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30
Study 16874214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 30
Study 12909380 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-CPR training (n=36)
Number of subjects: 74
Study 12909380 — intervention group
Group type: COMPARATOR
Intervention: Traditional CPR training (n=38)
Number of subjects: 74
Study 10877011 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 300 mg single oral dose in healthy controls
Number of subjects: 20
Study 10877011 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg single oral dose in malaria patients
Number of subjects: 20
Study 10877011 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg single oral dose in both groups
Number of subjects: 20
Study 10437215 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture and routine treatment (Group 1, n = 29)
Number of subjects: 59
Study 10437215 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment alone (Group 2, n = 30)
Number of subjects: 59
Study 10437215 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ICVD, n = 38)
Number of subjects: 59
Study 8259875 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2a (INF-alpha-2a) 50,000 IU/kg/day
Number of subjects: 52
Study 8259875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52